SBRT for Ultra-Central NonSmall Cell Lung Cancer
Part of paid clinical trials in Washington D.C., District of Columbia.
- Sponsor
- Georgetown University
- Study ID
- NCT07852247
- Phase
- PHASE1
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Nonsmall Cell Lung Cancer Stage
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- SBRT — RADIATION50 Grays (Gy) delivered in 5 fractions, delivered using Cyberknife with Synchrony motion tracking, every other day over 2 weeks.
Study Details
The goal of this clinical trial is to find out if Five-fraction CyberKnife stereotactic body radiation therapy (SBRT) with real-time Synchrony® motion tracking can treat ultra-central nonsmall cell lung cancer while reducing the amount of serious side effects from SBRT. Participants will * receive radiation treatment every other day over two weeks using a machine called the CyberKnife®, which uses a technology called Synchrony® motion management, which tracks your tumor in real time as it moves with your breathing. This allows the radiation beam to follow your tumor during treatment, helping to deliver the radiation more accurately to the tumor while reducing the dose to nearby healthy organs. * return for follow up visits after treatment at months 3, 6, 9, 12, 18, 24 and then every year for 5 years to be evaluated * complete questionnaires before and after treatment.
Key Dates
- First listed
- Oct 1, 2026
- Start date
- Nov 30, 2026
- Status verified
- Sep 2026
- Primary completion
- Nov 30, 2031
- Completion
- Nov 30, 2033
Study Design
- Enrollment
- 35 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Cyberknife with Synchrony Motion Tracking
Primary Outcome Measure
Cumulative incidence of grade 3 or higher toxicity following SBRT with CyberKnife regimen with real-time motion tracking for ultra-central NSCLC. [ Time Frame: Patients will be assessed for toxicity throughout treatment with radiation therapy (RT). Following RT, all participants will be evaluated through 12 months for the primary safety endpoint and will continue protocol safety follow-up through 5 years. ]
Central Contacts
- Jonathan Lischalk, MD2026879194
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Lombardi Comprehensive Cancer Center, Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | Jonathan Lischalk, MD (PRINCIPAL_INVESTIGATOR) |